Rheumatoid arthritis (RA) is the most common autoimmune inflammatory joint disease, with a prevalence of 1%. The etiology of RA is multifactorial and includes a significant genetic component, with a relative risk of recurrence of 5--10 in siblings of probands ([@b1]). Many genetic linkage and association studies have implicated a group of alleles of the DRB1 gene encoding a similar sequence, termed the shared epitope ([@b2],[@b3]). Recent evidence has also implicated the common allele of the R620W single-nucleotide polymorphism (SNP) (rs2476601) in the hematopoietic-specific protein tyrosine kinase, protein tyrosine phosphatase N22 (PTPN22), with susceptibility to several autoimmune diseases, including RA ([@b4]).

The severity of RA varies from mild self-limiting arthritis to an aggressive systemic disease associated with a significantly reduced life expectancy. Several validated systems for scoring radiographic damage are widely used to assess disease progression or severity, including the Sharp and Larsen scores ([@b5],[@b6]). More severe radiographic damage correlates with the presence of rheumatoid factor (RF) and anti--cyclic citrullinated peptide (anti-CCP) antibodies, with the presence of both being associated with more severe changes compared with the presence of either of the biomarkers alone ([@b7]). Longitudinal studies have revealed a strong correlation of total inflammation load, as assessed by C-reactive protein (CRP) levels over time, with greater radiographic damage ([@b8]). A recent report described the usefulness of measurement, at the time of disease presentation, of a range of biomarkers, including RF, anti-CCP antibodies, DRB1 alleles, and CRP and suggested that these variables could be used to predict damage to the hand and foot joints; however, the variance of radiographic joint damage that could be explained by these measurements was only 44% at 5 years and only 32% at 10 years, suggesting that other variables contribute to joint damage ([@b9]).

Relatively few studies have addressed the role of genetics in relation to radiographic joint damage. A small study compared the radiographic progression in monozygotic twins, dizygotic twins, and unrelated pairs of patients and found that variation was maximal in unrelated patients, followed by dizygotic twins, and was least in monozygotic twins, suggesting genetic input ([@b10]). A relationship between DRB1 alleles and disease severity has been reported, but recent evidence suggests that it is secondary to production of anti-CCP antibodies ([@b11]), particularly in RF-negative patients ([@b5]). Many studies have shown genetic associations with RA severity; however, these studies used different criteria to measure disease severity, such as the presence of rheumatoid nodules, a history of joint replacement surgery, earlier age at disease onset, or radiographic scoring methods. Furthermore, they mostly involved relatively small numbers of patients and did not assess the relationship with established biomarkers such as autoantibodies ([@b12]).

A central feature of RA is a relative imbalance of cytokine production, with a relative excess of proinflammatory molecules including interleukin-1 (IL-1), IL-6, and tumor necrosis factor (TNF) compared with antiinflammatory mediators such as IL-10 ([@b13]). The successful therapeutic use of inhibitors of proinflammatory cytokines underlines the importance of these molecules in driving rheumatoid inflammation and tissue damage. The production of these molecules is controlled at the levels of transcription, messenger RNA stability, and translational efficiency. Recently, selenoprotein S (SEPS) was identified as an important regulator of IL-1, TNF, and IL-6, with plasma levels of these proteins correlating with functional promoter single-nucleotide polymorphisms (SNPs) in SEPS ([@b14]).

In this genetic study, we examined whether SNPs in IL-1, IL-6, IL-10, PTPN22, and SEPS are associated with radiographic damage in a large cross-sectional cohort of patients with RA, and determined whether the associations detected were independent of production of RF and anti-CCP. Variants were chosen based on previous reports of functional relevance or associations with RA.

PATIENTS AND METHODS
====================

Patients
--------

Nine hundred sixty-four patients fulfilling the American College of Rheumatology (formerly, the American Rheumatism Association) criteria for the classification of RA ([@b15]) were recruited from the Royal Hallamshire Hospital, Sheffield, as previously described; 872 of these patients had erosive damage ([@b5]). Research Ethics Committee approval was obtained for the study, and all participants provided informed consent. Radiographs of the hands and feet were obtained at the time of study entry, and modified Larsen scores of radiographic damage progression were obtained as described previously ([@b5],[@b6]).

Measurement of antibodies
-------------------------

Measurement of antibodies was performed as previously described ([@b5]). Briefly, anti-CCP antibody levels were measured using the DIASTAT Anti-CCP enzyme-linked immunosorbent assay (Axis-Shield UK, Kimbolton, UK). A cutoff of 5.5 units/ml was established to define antibody positivity, based on the mean (+3 SD) of values obtained for 100 age-matched control subjects. RF was measured using a Dade-Behring BN2 nephelometer (Marburg, Germany).

Genotyping
----------

Genotyping of SNPs in the IL-1 gene cluster, IL-6, IL-10, PTPN22, SEPS +3705, and SEPS +5227 was performed using TaqMan assays designed by Applied Biosystems (Foster City, CA) ([Table 1](#tbl1){ref-type="table"}). Typing of SEPS −105 was performed commercially by personnel at KBiosciences (Herts, UK) using the KASPar method (<http://www.kbioscience.co.uk/chemistry/>) and primers 5′-GGACGCGGTCGTGGTCCC-3′ (C allele), 5′-GGACGCGGTCGTGGTCCT-3′ (T allele), and common primer 5′-GGTCGGCCTGCGATTGGCC-3′. To ensure high-quality genotyping results, we included multiple positive controls (sequenced templates) and negative controls (ultrapure water templates) in all genotyping plates, 10% of assays were repeated for quality control purposes, and no discrepancies were found. One allelic TaqMan probe was labeled with fluorescent FAM dye and the other with VIC dye ([Table 2](#tbl2){ref-type="table"}). The total reaction volume was 5 μl, containing 10 ng of genomic DNA. Thermal cycling in 384-well plates was performed using a PTC-225 DNA Engine Tetrad thermal cycler (MJ Research, San Francisco, CA), and genotypes were determined using an ABI Prism 7900HT Sequence Detection System (Applied Biosystems).

###### 

Details of individual single-nucleotide polymorphisms (SNPs)

  SNP number       Gene       Description
  ---------------- ---------- --------------------------------
  rs17561          *IL1*α     Ser^114^Ala
  rs16944          *IL1*β     Promoter (−511)
  rs1143634        *IL1*β     Synonymous coding, Phe^105^Phe
  rs419598         *IL1RN*    Synonymous coding, Ala^39^Ala
  rs1800872        *IL10*     Promoter (−592)
  rs1800896        *IL10*     Promoter (−1082)
  rs1800795        *IL6*      Promoter (−174)
  rs2476601        *PTPN22*   Arg^620^Trp
  Not applicable   *SEPS*     5′-untranslated region
  rs4965814        *SEPS*     Intron 5
  rs4965373        *SEPS*     3′-untranslated region

###### 

Sequences and concentrations of oligonucleotide primers and probes, and annealing temperatures used in polymerase chain reactions for TaqMan-based genotyping[\*](#tf2-1){ref-type="table-fn"}

  SNP              Forward primer, 5′→3′          μ*M*   Reverse primer, 5′→3′             μ*M*   Probe, 5′→3′                          μ*M*   Temp.
  ---------------- ------------------------------ ------ --------------------------------- ------ ------------------------------------- ------ -------
  *PTPN22* +1858   CCAGCTTCCTCAACCACAATAAATG      36     CAACTGCTCCAAGGATAGATGATGA         36     VIC--TCAGGTGTCCATACAGG                8      60°C
                                                                                                  FAM--TCAGGTGTCCGTACAGG                8      
  *IL1* −511       GTCTCTACCTTGGGTGCTGTTC         36     GAGGCTCCTGCAATTGACAGA             36     VIC--TCTGCCTCAGGAGCT                  8      60°C
                                                                                                  FAM--CTGCCTCGGGAGCT                   8      
  *IL1* +3954      ACCTAAACAACATGTGCTCCACA        36     ATCGTGCACATAAGCCTCGTTA            36     VIC--CATGTGTCGAAGAAGA                 8      60°C
                                                                                                  FAM--CATGTGTCAAAGAAGA                 8      
  *IL1* +4845      TCTGCACTTGTGATCATGGTTTTAGA     36     TGTATTTCACATTGCTCAGGAAGCT         36     VIC--CTAGGTCAGCACCTTT                 8      60°C
                                                                                                  FAM--CCTAGGTCATCACCTTT                8      
  *IL1RN* +2018    GGGATGTTAACCAGAAGACCTTCTATCT   25     CAACCACTCACCTTCTAAATTGACATT       25     TET--ACAACCAACTAGTTGCCGGATACTTGC      17.5   64°C
                                                                                                  FAM--AACAACCAACTAGTTGCTGGATACTTGCAA   5      
  *IL10* −592      GGTAAAGGAGCCTGGAACACATC        36     GCCCTTCCATTTTACTTTCCAGAGA         36     VIC--CCCGCCTGTACTGTAG                 85     60°C
                                                                                                  FAM--CCGCCTGTCCTGTAG                  8      
  *IL10* −1082     GATAGGAGGTCCCTTACTTTCCTCTTA    5      CACACACAAATCCAAGACAACACTAC        30     TET--CCTACTTCCCCTTCCCAAAGAAGCC        15     63°C
                                                                                                  FAM--CTACTTCCCCCTCCCAAAGAAGCCT        5      
  *IL6* −174       GACGACCTAAGCTGCACTTTTC         36     GGGCTGATTGGAAACCTTATTAAGATTG      36     VIC--CTTTAGCATGGCAAGAC                8      60°C
                                                                                                  FAM--CTTTAGCATCGCAAGAC                8      
  *SEPS* +3705     GCCAGGTTTAGTCTTCTGACACAAA      36     AGCAGGGCCACAGACTTG                36     VIC--CTGACCTTAAACGCTGAGC              8      60°C
                                                                                                  FAM--CTGACCTTAAACACTGAGC              8      
  *SEPS* +5227     TTGCCAGACTTATTTTGGGTGAGT       36     TTCAAGGAGATTTATGGACTTCAATTTGTCT   36     VIC--TTTTTATTACAACCTCTAACTATT         8      60°C
                                                                                                  FAM--TTACAACCTCCAACTATT               8      

SNP = single-nucleotide polymorphism; temp. = temperature.

Statistical analysis
--------------------

Hardy-Weinberg equilibrium was examined using the chi-square goodness-of-fit test. Pearson\'s chi-square test was used to compare allele/genotype carriership between patients and control subjects, and crude odds ratios are presented with 95% confidence intervals. For each DNA variant, the most prevalent homozygous genotype was chosen as the baseline reference.

Dichotomized variables were created for RF and anti-CCP levels (for RF positivity, ≥40 IU/ml; for anti-CCP positivity, ≥5.5 units/ml), and Pearson\'s chi-square test was used to test for association between allele/genotype and autoantibody seropositivity in patients with RA. Larsen scores of radiographic damage in patients with RA were tested for associations with candidate gene polymorphisms as well as RF and anti-CCP. The Shapiro-Francia test for normality was applied to the data and showed strong evidence against the assumption of normality for the modified Larsen score distribution.

The Kruskal-Wallis nonparametric test was therefore used to compare median scores across genotype groups, followed by the Cuzick nonparametric test for trend to assess gene-dose effects. Genotypes were coded as 0, 1, and 2 for the most prevalent homozygous, heterozygous, and variant homozygous genotypes, respectively. Quantile regression was carried out to estimate the proportion of variance of the different variables in relation to the modified Larsen score. Quantile regression is a complement to classic linear regression, in which the primary goal is to determine the conditional mean of a random variable y, given some explanatory variable x. In quantile regression, one determines the conditional quantile distribution of the y variable; of most common interest is measurement of the 50% quantile or median. All statistical analyses were carried out using Stata statistical software, release 9.1 (Stata Corporation, College Station, TX).

RESULTS
=======

The study cohort consisted of 964 patients, whose characteristics at baseline are detailed in [Table 3](#tbl3){ref-type="table"}. Genotyping data for the SEPS −105 SNP were available for 509 patients; for all other markers, data were available for 856--940 patients in the cohort (89--98%). All genotyping results fit Hardy-Weinberg equilibrium. Because Larsen scores did not fit a normal distribution, we compared median scores across the 3 genotypes. The Shapiro-Francia test for normality was applied to the data and showed strong evidence against the assumption of normality for Larsen score distribution. The Kruskal-Wallis nonparametric test was then applied to test for median Larsen score differences across genotypes of each variant, followed by the Cuzick nonparametric test for trend when a gene-dose effect was observed. Genotypes were coded as 0, 1, and 2 for the most prevalent homozygous, heterozygous, and variant homozygous genotypes, respectively.

###### 

Baseline clinical characteristics of the patients with rheumatoid arthritis[\*](#tf3-1){ref-type="table-fn"}

  ------------------------------------------------------ -------------
  No. of patients                                        964
  Age, mean ± SD years                                   61.3 ± 12.3
  Disease duration, mean ± SD years                      15.6 ± 10.7
  Female sex, no. (%)                                    695 (72.1)
  Male sex, no. (%)                                      269 (27.9)
  Rheumatoid factor positive, no. (%)                    604 (68.4)
  Rheumatoid factor negative, no. (%)                    279 (31.6)
  Anti--cyclic citrullinated peptide positive, no. (%)   697 (76.3)
  Anti--cyclic citrullinated peptide negative, no. (%)   217 (23.7)
  ------------------------------------------------------ -------------

Rheumatoid factor status was determined in 883 patients, while antibody status was determined in 914 patients.

The frequency of the IL-6 −174G allele was 55%, and an allele-dose association with increasing radiographic damage was present (*P* = 0.005), with patients with the GG genotype having the highest median modified Larsen score ([Table 4](#tbl4){ref-type="table"}). Strong linkage disequilibrium was detected between the 2 IL-10 SNPs (D′ = 0.89 and r^2^ = 0.24), with allele frequencies of 55% and 79% for IL-10 −1082G and −592, respectively. The IL-10 −592CC genotype was associated with greater damage compared with the AC genotype, and the AA genotype was associated with an intermediate score for damage (*P* = 0.006). An allele-dose association of IL-10 −1082 with damage was observed, but the difference in median scores between genotypes (*P* = 0.01) was less than that for IL-10 −592. A relatively weak association of PTPN22 +1858T was detected (*P* = 0.04). The allele frequency of PTPN22 +1858T was 17%, and only a small number of patients had the TT genotype. Radiographic damage increased in an allele-dose manner, with the lowest scores in patients with the PTPN22 +1858CC genotype.

###### 

Genotypes and modified Larsen scores of radiographic damage

  Gene                     Genotype   Patients, no. (%)   Median modified Larsen score[\*](#tf4-1){ref-type="table-fn"}   *P*
  ------------------------ ---------- ------------------- --------------------------------------------------------------- ---------------------------------------
  *PTPN22* (n = 901)       TT         31 (3.4)            50.0                                                            
                           TC         238 (26.4)          33.0                                                            0.04[†](#tf4-2){ref-type="table-fn"}
                           CC         632 (70.1)          25.5                                                            
  *IL10* −592 (n = 928)    AA         32 (3.4)            27.5                                                            
                           AC         309 (33.3)          22.0                                                            0.006
                           CC         587 (63.3)          32.0                                                            
  *IL10* −1082 (n = 860)   AA         186 (21.6)          24.0                                                            
                           AG         415 (48.3)          27.0                                                            0.01[†](#tf4-2){ref-type="table-fn"}
                           GG         259 (30.1)          31.0                                                            
  *IL1RN* (n = 831)        CC         39 (4.7)            36.0                                                            
                           TC         334 (40.2)          29.0                                                            0.4[†](#tf4-2){ref-type="table-fn"}
                           TT         458 (55.1)          27.5                                                            
  *IL6* −174 (n = 930)     CC         166 (17.8)          25.0                                                            
                           CG         482 (51.8)          27.0                                                            0.005[†](#tf4-2){ref-type="table-fn"}
                           GG         282 (30.3)          33.5                                                            
  *IL1* −511 (n = 932)     GG         89 (9.5)            33.0                                                            
                           GA         421 (45.2)          27.0                                                            0.8
                           AA         422 (45.3)          28.0                                                            
  *IL1* +3954 (n = 880)    TT         37 (4.2)            49.0                                                            
                           TC         332 (37.7)          22.0                                                            0.1
                           CC         511 (58.1)          29.0                                                            
  *IL1* +4845 (n = 916)    TT         64 (7.0)            31.0                                                            
                           GT         398 (43.4)          27.0                                                            0.8
                           GG         454 (49.6)          28.0                                                            
  *SEPS* −105 (n = 509)    TT         8 (1.6)             49.5                                                            
                           CT         128 (25.1)          31.0                                                            0.6
                           CC         373 (73.3)          33.0                                                            
  *SEPS* +3705 (n = 934)   TT         24 (2.6)            44.5                                                            
                           CT         282 (30.2)          28.0                                                            0.2
                           CC         628 (67.2)          28.0                                                            
  *SEPS* +5227 (n = 888)   GG         99 (11.1)           27.0                                                            
                           GA         398 (44.8)          30.5                                                            0.4
                           AA         391 (44.0)          26.0                                                            

Maximum possible score is 160.

By Cuzick\'s test for trend.

Dichotomized variables were created for both RF and anti-CCP (for RF positive, ≥40 IU/ml; for anti-CCP positive, ≥5.5 units/ml). Pearson\'s chi-square test was used to test for association between genotypes and seropositivity. To determine whether the genetic associations with radiographic damage were secondary to the production of RF and anti-CCP antibodies, genotypes were compared between antibody-positive and antibody-negative patients ([Table 5](#tbl5){ref-type="table"}). There was a weak association of PTPN22 +1858TT with anti-CCP positivity (*P* = 0.01); however, no other genotypes were significantly associated with antibody production, indicating that the genetic associations were independent of these well-established markers of RA severity.

###### 

Genotype frequencies and autoantibody status[\*](#tf5-1){ref-type="table-fn"}

  Gene             Genotype   Anti-CCP positive   Anti-CCP negative   OR (95% CI)       *P*                                    RF positive   RF negative   OR (95% CI)      *P*
  ---------------- ---------- ------------------- ------------------- ----------------- -------------------------------------- ------------- ------------- ---------------- -------------------------------------
  *PTPN22* +1858   TT         29                  2                   5.2 (1.3--45.7)   0.01[†](#tf5-2){ref-type="table-fn"}   23            5             2.2 (0.8--7.4)   0.1[†](#tf5-2){ref-type="table-fn"}
                   TC         177                 50                  1.3 (0.9--1.9)                                           138           76            0.9 (0.6--1.2)   0.3
                   CC         446                 161                                                                          404           190                            
  *IL10* −592      AA         28                  6                   1.5 (0.6--4.5)    0.5[†](#tf5-2){ref-type="table-fn"}    25            8             1.4 (0.6--3.7)   0.6[†](#tf5-2){ref-type="table-fn"}
                   AC         222                 72                  1.0 (0.7--1.4)    0.9                                    191           96            0.9 (0.7--1.2)   0.5
                   CC         432                 138                                                                          375           169                            
  *IL10* −1082     AA         138                 36                  1.1 (0.7--1.9)    0.6                                    120           52            1.1 (0.7--1.8)   0.6
                   AG         291                 113                 0.8 (0.5--1.1)    0.2                                    253           129           1.0 (0.7--1.4)   0.8
                   GG         191                 57                                                                           159           78                             
  *IL6* −174       CC         120                 40                  0.9 (0.6--1.5)    0.7                                    98            56            0.7 (0.5--1.1)   0.1
                   CG         351                 112                 1.0 (0.7--1.4)    0.9                                    304           140           0.9 (0.6--1.3)   0.6
                   GG         207                 64                                                                           184           77                             

The presence of anti--cyclic citrullinated peptide (anti-CCP) and rheumatoid factor (RF) was compared for each single-nucleotide polymorphism with reference to the commonest genotype. OR = odds ratio; 95% CI = 95% confidence interval.

By Fisher\'s exact test for association.

The relationship between antibody status, genotype, and radiographic damage was examined ([Table 6](#tbl6){ref-type="table"}). Carriers of IL-10 --592 AC and AA were pooled together because of small numbers. Homozygosity for IL-10 −592C was associated with more severe radiographic damage only in anti-CCP--negative patients (*P* = 0.002) and in RF-negative patients (*P* = 0.002). Conversely, the IL-6 −174G allele was associated with more severe disease only in anti-CCP--positive (*P* = 0.004) patients and RF-positive patients (*P* = 0.01), with an allele-dose effect. Marginally significant associations of PTPN22 +1858T and IL-10 −1082G were also detected.

###### 

Modified Larsen scores across genotypes, according to anti-CCP and RF status[\*](#tf6-1){ref-type="table-fn"}

                   Anti-CCP positive                       Anti-CCP negative   RF positive                            RF negative
  ---------------- --------------------------------------- ------------------- -------------------------------------- --------------------------------------
  *PTPN22* +1858                                                                                                      
      TT/TC        31.0 (206)                              20.0 (50)           42.0 (161)                             19.0 (81)
      CC           37.5 (445)                              8.5 (158)           33.5 (404)                             13.0 (188)
      *P*          0.5                                     0.04                0.2                                    0.07
  *IL10* −592                                                                                                         
      AA/AC        29.0 (250)                              6.0 (76)            31.0 (216)                             11.0 (103)
      CC           37.0 (431)                              16.0 (135)          40.0 (375)                             18.5 (168)
      *P*          0.06                                    0.002               0.05                                   0.002
  *IL10* −1082                                                                                                        
      AA           27.5 (138)                              6.0 (36)            29.5 (120)                             8.0 (52)
      AG           33.5 (290)                              15.5 (110)          37.0 (253)                             16.0 (127)
      GG           38.0 (191)                              10.0 (55)           38.0 (159)                             17.5 (78)
      *P*          0.02[†](#tf6-2){ref-type="table-fn"}    0.2                 0.1[†](#tf6-2){ref-type="table-fn"}    0.03[†](#tf6-2){ref-type="table-fn"}
  *IL6* −174                                                                                                          
      CC           29.0 (120)                              13.0 (39)           30.00 (98)                             13.00 (56)
      GC           32.0 (350)                              13.0 (109)          34.00 (304)                            13.00 (139)
      GG           41.0 (207)                              10.0 (63)           44.00 (184)                            10.00 (76)
      *P*          0.004[†](#tf6-2){ref-type="table-fn"}   0.9                 0.01[†](#tf6-2){ref-type="table-fn"}   0.9

Values are the median Larsen scores (number of carriers). Anti-CCP = anti--cyclic citrullinated peptide; RF = rheumatoid factor; IL-10 = interleukin-10.

By Cuzick\'s test for trend.

Finally, the proportion of variance in modified Larsen scores was calculated using the correlation coefficient value (R^2^). As expected in this cross-sectional study, disease duration was the most significant (20%), followed by RF (3%) or anti-CCP status (2%), IL-6 −174 (0.8%), and IL-10 −592 (0.4%).

DISCUSSION
==========

Established biomarkers for RA severity include RF, anti-CCP, and DRB1 genotypes; however, these explain a relatively small proportion of the variance in disease severity ([@b9]). Use of genetic markers predictive of severity has several advantages over use of conventional biomarkers; genotypes are stable, measurable at disease onset, and are amenable to high-throughput assays. Biomarkers can be used to measure inflammation load or bone and cartilage turnover in RA; for example, radiographic damage correlates with the time-averaged C-reactive protein levels ([@b8]). New treatments of RA have proven very effective for the treatment of severe disease, but their more widespread use is limited by cost in many countries. Clinically, there is a need to identify additional markers that may be predictive of the outcome of severe disease; such markers could be used to target these new treatments to patients at risk of severe RA. In this study, we examined the association of functional genetic variants in 5 candidate RA genes with radiographic damage, and evaluated whether associations were independent of established biomarkers.

The proinflammatory cytokine IL-6 has a range of pleiotropic activities, including the induction of acute-phase proteins, stimulation of T cells and B cells (including the differentiation and activation of immunoglobulinproducing plasma cells), and the stimulation of synoviocytes and osteoclasts, with resultant damage to cartilage and bone ([@b16]). High levels of IL-6 have been reported in RA serum and synovial tissue ([@b17]). Furthermore, serum levels of IL-6 have been correlated with the erythrocyte sedimentation rate and the platelet count ([@b18]). Our finding of a gene-dose association of IL-6 −174G with radiographic damage may be a consequence of the higher gene expression that has been associated with this allele ([@b19]). The IL-6 −174G allele has been associated with susceptibility to systemic-onset juvenile RA in both a large case--control study ([@b19]) and a family-based association study ([@b20]) but not with susceptibility to RA ([@b21]), although it has been associated with a greater inflammation load in RA as assessed by modified Disease Activity Scores as measured in 28 joints ([@b22],[@b23]).

IL-10 is produced predominantly by monocytes and lymphocytes and has a range of antiinflammatory and immunoregulatory properties, including inhibition of synthesis of proinflammatory molecules such as TNF, IL-1, and IL-6 ([@b24]). Because of these properties, IL-10 was originally named cytokine synthesis inhibitor factor. Production of IL-10 by rheumatoid synovial macrophages and T cells inhibits production of IL-1 and TNF by synovial cells ([@b25]), and increased relative expression of IL-10 has been reported in joints without erosion compared with those with erosion, suggesting a protective role in RA ([@b26]).

Studies in animal models of RA have also demonstrated an antiinflammatory role of IL-10 ([@b27],[@b28]). Genetic factors explain ∼75% of the population variation in IL-10 production ([@b29]). Secretion of IL-10 has been correlated with individual promoter SNP genotypes and haplotypes ([@b30],[@b31]). Genotypes associated with IL-10 production have been associated with susceptibility to RA ([@b32]); however, these findings have not been replicated in other populations ([@b33]). Our data are consistent with those from a Dutch prospective study of 91 female patients with RA followed up for 12 years, in whom radiographic damage to the hands and feet progressed more rapidly in individuals homozygous for −1082G compared with those homozygous for −1082A ([@b26]). Furthermore, this study also demonstrated lower production of IL-10 in whole blood cultures of individuals with the GG genotype compared with the AA genotype, suggesting that the association of −1082G with radiographic damage is related to lower IL-10 production.

Seropositivity for both RF and anti-CCP is associated with development of more severe erosive RA ([@b5]), raising the possibility that our findings of an association of IL-6 and IL-10 genotypes with the modified Larsen score may be secondary to the production of these autoantibodies. However, RF and anti-CCP status was not associated with IL-6 or IL-10 genotypes, indicating that the genetic associations are independent of these markers of radiographic damage.

In our study, the association between the Larsen score and the IL-6 genotype was observed only in patients who were RF negative and/or anti-CCP seropositive (i.e., patients with more severe disease). Conversely, the association between the IL-10 genotype and the Larsen score was present only in patients who were RF negative and/or anti-CCP seronegative (i.e., those with milder disease). These findings may allow insights into the pathogenesis of RA, as well as having potential clinical importance. On the basis of these results, we propose that autoantibody-specific B cells occupy a more upstream position in the processes resulting in the development of RA, and that the influence of particular cytokine polymorphisms on disease phenotype is dependent on their presence or absence. This paradigm is broadly aligned with several recent studies demonstrating the presence of antibodies preceding disease onset ([@b34]). From a practical point of view, we suggest that the potential clinical utility of genotyping for the IL-6 and IL-10 polymorphism would depend on RF and anti-CCP status.

The PTPN22 +1858T allele has been associated with susceptibility to autoimmune diseases including systemic lupus erythematosus, type 1 diabetes mellitus, Graves\' disease, and RA ([@b4]). An area of controversy relates to the association of this variant with RF production. Several groups of investigators reported a genetic association restricted to RF-positive patients [@b4],[@b35]), while other investigators reported that the association is independent of RF status ([@b36],[@b37]). We did not observe an association of PTPN22 +1858T with RF status but detected an association of anti-CCP status consistent with that reported by Plenge et al ([@b35]).

The cross-sectional design of this study using an RA cohort with established disease did not permit us to examine whether the IL-6 and IL-10 genotypes are associated with a linear increased level of joint damage over time rather than perhaps primarily being important at an early time period; such an assessment will require a prospective study design. Further large prospective studies should clarify the clinical usefulness of genotyping for these SNPs, particularly their potential role in therapeutic targeting of expensive antirheumatic drugs to patients at risk of developing more severe RA.
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